A phase 3 trial found that switching from bictegravir–emtricitabine–tenofovir alafenamide to once-daily bictegravir–lenacapavir maintained viral suppression in adults with HIV-1.
April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
A large national database study presented at CROI 2026 in Denver, CO, reports that 5-year survival remains lower for people with HIV compared with people without HIV across most treatment modalities for...
A large US cohort study examined hepatitis B virus (HBV) monitoring practices and the risk of HBV reactivation and hepatitis flares during interruptions of tenofovir-containing antiretroviral therapy among...
In the phase 3 ACTG A5359 LATITUDE trial, investigators evaluated whether monthly, long-acting injectable cabotegravir plus rilpivirine could reduce regimen failure compared with standard oral...
A large cross-sectional Italian study evaluated the prevalence of cognitive frailty and identified HIV-specific and clinical risk factors among adults 50 years or older living with HIV, highlighting the...
In a large multicountry trial, researchers evaluated whether an integrase inhibitor–based regimen offers comparable or superior treatment outcomes to a boosted protease inhibitor regimen in adults with...
A national analysis presented at the 2025 AHA Scientific Sessions found that patients with HIV hospitalized with cardiac implantable electronic device–related infective endocarditis had significantly lower...
